Mosaic comes out of stealth with $47M to teach catheters to find their own way through blood vessels

Mosaic Intelligence Labs, a San Francisco surgical-robotics startup, said on Nov. 10, 2026, that it emerged from stealth with $47 million in seed funding from investors including 8VC, Fundomo, Lingotto Innovation and Obvious Ventures to build sensing-enabled instruments, 3D spatial intelligence and robotic control for procedures performed through blood vessels.

Endovascular surgery already reaches almost any organ through a needle-sized hole; the hard part is steering blind through the plumbing with X-ray and feel. Mosaic's pitch is instruments that can sense where they are and get smarter with every case. It's a $47M seed with no product, no trial and no FDA filing yet — the founders have money and a thesis, and the hard part (proving it in patients) is still ahead.

Mosaic Intelligence Labs, a surgical-robotics startup in San Francisco, said it emerged from stealth with $47 million in seed funding. A seed round is the early money that lets a company start building, before a product is for sale. Investors include 8VC, Fundomo, Lingotto Innovation, and Obvious Ventures. The Information, as The Next Web reported it, said the money came in two seed rounds, led by 8VC and Fundomo. The company is about one year old. It did not disclose a valuation, the price a round puts on the whole company. The announcement is dated Nov. 10, 2026. The round size and the investor names are the company's. The two-round split and the age are The Information's, via The Next Web.

The first job is endovascular intervention. Physicians guide thin, flexible wires and catheters through blood vessels to deliver treatment. A catheter is a thin tube. Blood vessels reach virtually every organ. Inside them, a doctor has no direct line of sight. The view is live X-ray, scans taken before the operation, and the feel of the instruments in the hands. Learning to read those signals takes years. The X-ray is radiation. Outcomes vary with how experienced the person holding the wire is. Those lines are the company's.

The approach is to put sensors where the instruments meet the body, and to add computation that rebuilds the vessel's shape from the inside. The platform is designed to give a physician a 3D view of the anatomy and of where the instrument sits, updated as the case goes on, plus a robotic interface for precise control. 3D, here, means a picture with depth, not a flat X-ray. Chief executive Ileana Pirozzi told The Information that the semi-autonomous catheter can "find its own way." Its tip bends to follow the right vessels as the surgeon feeds it in. The Next Web carried that account. The surgeon is still the one feeding the catheter. This is a tool that steers with the surgeon, not a machine operating on its own.

The other half of the pitch is a learning loop. The system would capture synchronized data on the environment, how the instrument moves, and what the physician does, then combine that with physical models. The point is that a machine can relate what it senses to what happens when it moves. The company calls this a surgical world model, a running picture of the place the tool is in. It also uses the word umwelt, the slice of the world a creature can actually perceive. Those lines are Mosaic's.

Pirozzi, co-founder and chief executive, is quoted: "We kept returning to one question: what would it take to scale the knowledge of the very best surgeons? We believe that starts with making our machines aware, and turning surgical repetition into experience we can learn from." Alison "Ali" Kight Mackanic, co-founder and chief technology officer, is quoted: "There is no evolving loop between perception and action, and as a result they are structurally locked out of the ability to become intelligent." She is describing instruments that can be moved, but that never update from the last case. Those quotations are theirs, in the announcement.

The two founders met during doctoral studies at Stanford, working alongside clinicians. A clinician is a doctor or another person who treats patients. Those lines are the company's.

Further out, a catheter can carry drugs, energy, biologics, and other therapies to a target. Biologics are medicines made from living systems, such as proteins. Better navigation could widen what gets delivered through a vessel, and which organs are in reach. That is the company's longer-term case. It is not a product with a ship date.

Mosaic is hiring engineers, physicians, and creatives in San Francisco, across hardware, sensing, perception, machine learning, and clinical engineering. Machine learning is software that finds patterns in examples and updates from them. The company says people on the team have built surgical systems used on more than 20 million patients, and have also built rockets, cars, artificial hearts, and drugs. Those lines are Mosaic's. The announcement does not name a product, a price, a launch date, a clinical trial, or a filing with the FDA. There is no patient result in the release. The work is in development.

The picture is Dr. Ileana Pirozzi and Dr. Alison Mackanic standing outdoors, arms crossed, with greenery behind them. The credit is Mosaic Intelligence Labs, as carried by The Next Web.

In plain terms, two Stanford PhDs came out of stealth with $47 million to build catheters that can sense where they are inside a blood vessel and get better at the job as surgeons use them. The surgeon still feeds the tool in. There is no named product, no trial, and no FDA filing in the announcement. The money and the thesis are public. The proof in patients is not.